Combination Of High Dose QUADRAMET(R) And Chemotherapy Shows Promise For Treatment Of High-Risk Acute Myeloid Leukemia

... Cytogen Corporation (Nasdaq: CYTO) today announced the publication of new data relating to the Company's QUADRAMET(R) (samarium Sm-153 lexidronam injection) product. The publication, "Marrow irradiation with high-dose 153 Samarium-EDTMP followed by chemotherapy and hematopoietic stem cell infusion for acute myelogenous leukemia" by Vilmarie Rodriguez, M.D. [click link for full article] ...